查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988337

分子診斷市場自動化：按產品類型、技術、自動化程度、應用和最終用戶分類的全球市場預測，2026-2032 年

Automation in the Molecular Diagnostics Market by Product Type, Technology, Automation Level, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年自動化分子診斷市值為157.8億美元，預計2026年將成長至183.9億美元，複合年成長率為16.66%，到2032年將達到464.2億美元。

主要市場統計數據
基準年 2025 157.8億美元
預計年份：2026年 183.9億美元
預測年份 2032 464.2億美元
複合年成長率 (%) 16.66%

分子診斷自動化如何重新定義臨床和研究環境中的檢查室工作流程、品質期望和策略重點。

在分子檢查室中，自動化不再只是循序漸進的改進，而已成為影響臨床處理能力、資料完整性和營運韌性的策略必需品。機器人技術、整合樣本處理和雲端數據分析的進步，以及不斷變化的臨床需求，共同創造了一個有利於檢查室縮短處理時間、標準化通訊協定並提供更快、更可重複結果的環境。因此，自動化不僅影響日常運營，也影響資本投資規劃、人才培育和供應商選擇。

分子診斷領域正在發生重大變革，而推動變革的因素包括整合自動化、可互通軟體以及不斷變化的臨床和營運需求。

在分子診斷領域，技術成熟、工作流程整合和不斷變化的臨床需求正在推動變革。定序平台和高通量PCR系統如今已與微陣列解決方案和從檢體到結果的先進數據分析工具相輔相成，使檢查室能夠擴展檢測項目並縮短週轉時間。同時，軟體編配和基於雲端的分析技術能夠以更高的透明度和可審計性管理複雜的多儀器工作流程。

評估美國關稅政策變化對診斷設備製造商和檢查室。

美國近期關稅趨勢和貿易政策的變化正在影響分子診斷設備、耗材和軟體的採購和供應。檢查室和診斷設備供應商面臨著不斷變化的成本結構，這影響著他們的供應商選擇、庫存策略和合約談判。隨著關稅改變進口零件和成品的相對經濟效益，各機構正在重新評估其供應商所在地，並探索替代製造地和本地庫存策略，以降低風險並維持醫療服務的連續性。

全面的細分分析揭示了產品類型、最終用戶、技術、自動化程度和應用如何決定採用率、價值和供應商策略。

細分市場分析揭示了產品類型、最終用戶、技術、自動化程度和應用領域如何影響整個診斷生態系統的部署模式和價值實現。根據產品類型，所提供的產品涵蓋耗材和試劑（包括微陣列晶片、次世代定序(NGS)樣品製備試劑盒和 PCR 試劑盒）、儀器（例如微陣列系統、NGS 儀器和 PCR 儀器）以及軟體和服務（包括數據分析平台、整合服務和託管服務）。這些類別相互關聯；儀器部署通常會推動對耗材的持續需求，而軟體和服務則有助於實現更高價值的應用情境和營運擴充性。

區域洞察顯示美洲、歐洲、中東和非洲以及亞太地區不同的臨床基礎設施、採購慣例和法規環境如何影響自動化的採用和商業化。

區域趨勢正在影響分子診斷領域的技術應用、報銷途徑和供應鏈優先事項。在美洲，先進的檢查室網路和一體化參考實驗室正在推動對高通量自動化和整合數據平台的需求。同時，對基礎設施的投資和對規模化的重視正在促進與以服務和本地支援為重點的供應商建立夥伴關係。相較之下，歐洲、中東和非洲（EMEA）地區的情況則更為複雜。儘管許多市場正在推進法規結構的協調統一和基因組學相關舉措的集中化，但基礎設施的差異和分散的採購慣例使得市場需要能夠在各種臨床環境中運行的靈活模組化解決方案。

主要企業的策略揭示了平台整合、模組化架構、卓越的服務和監管專業知識如何提供競爭優勢，並在供應商選擇中脫穎而出。

分子診斷自動化領域的主要企業正採用差異化策略，以反映其技術優勢、服務模式和打入市場策略。一些供應商優先採用基於平台的方案，將儀器、耗材和軟體整合在一起，以確保長期永續的收入，並確保端到端工作流程的檢驗。另一些供應商則透過模組化和開放式架構系統來吸引客戶，這些系統能夠柔軟性組合來自多個供應商的儀器。無論採用哪種方案，對連接性、遠端監控和生命週期服務的投資都日益成為決定競爭優勢的重要因素。

為實驗室經營團隊和供應商提供實用建議，以使自動化投資與臨床優先事項、供應鏈彈性、勞動力轉型和互通性目標保持一致。

產業領導者應採取積極主動的方式，確保在臨床、營運和商業領域充分受益於自動化，同時有效管控風險。首先，應透過試點處理大批量、高影響力檢測並能縮短處理時間、減少誤差且結果可重複的解決方案，使自動化投資與臨床優先事項保持一致。同時，應制定人員轉型計劃，對檢查室人員進行再培訓，使其掌握自動化監控、數據解讀和設備維護等技能，從而最大限度地提高技術投資回報。

結合相關人員訪談、技術檢驗、二手文獻和情境分析，採用嚴謹的混合方法研究途徑，得出了可靠且可操作的見解。

本調查方法整合了第一手和第二手調查、定性訪談以及技術檢驗，以確保獲得可靠且可操作的見解。第一手調查包括對臨床、醫院、參考實驗室、製藥和研究機構的實驗室經理、採購經理和高級技術人員進行結構化訪談，以收集關於自動化促進因素、障礙和實施結果的第一手觀點。這些訪談為深入分析工作流程需求、人員配置影響和技術選擇標準奠定了基礎。

結論強調了在整個檢查室環境中進行策略性自動化如何改變診斷能力、營運彈性和臨床價值的提供。

分子診斷自動化已從一項提升效率的小眾措施發展成為檢查室策略的核心要素，它影響醫療機構提供診斷、管理風險以及在以價值為導向的醫療環境中競爭的方式。整合自動化減少了人為操作的差異，提高了處理能力，並實現了以往受限於人員和儀器分散的複雜基因組工作流程。因此，策略性地實施自動化的檢查室在報告速度、結果可重複性以及將新型檢測方法推廣到常規操作的能力方面都獲得了優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 分子診斷市場：依產品類型分類

  • 耗材和試劑
    • 微陣列晶片
    • NGS樣品製備盒
    • PCR試劑盒
  • 裝置
    • 微陣列系統
    • NGS設備
    • PCR設備
  • 軟體服務
    • 數據分析軟體
    • 綜合服務
    • 託管服務

第9章 分子診斷市場：依技術分類

  • 微陣列
  • NGS
  • PCR

第10章 分子診斷市場：依自動化程度分類

  • 全自動系統
  • 半自動系統
  • 無人值守自動化

第11章 分子診斷市場：依應用分類

  • 心血管疾病
  • 基因檢測
  • 感染疾病
  • 腫瘤學
  • 女性健康

第12章 分子診斷市場：依最終用戶分類

  • 臨床檢查室
  • 醫院檢查室
  • 製藥和生物技術公司
  • 標準檢驗組織
  • 研究所

第13章 分子診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 分子診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 分子診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國分子診斷市場

第17章：中國分子診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaltis Srl
  • altona Diagnostics GmbH
  • AstraGene LLC
  • Becton, Dickinson and Company
  • Biocartis NV
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Hudson Robotics, Inc.
  • Laboratory Corporation of America Holdings
  • MEGAROBO technologies Co., Ltd.
  • Olympus Corporation
  • Synchron Lab Automation
  • Sysmex Corporation
  • Waters Corporation
Product Code: MRR-2D1F5C65740B

The Automation in the Molecular Diagnostics Market was valued at USD 15.78 billion in 2025 and is projected to grow to USD 18.39 billion in 2026, with a CAGR of 16.66%, reaching USD 46.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.78 billion
Estimated Year [2026] USD 18.39 billion
Forecast Year [2032] USD 46.42 billion
CAGR (%) 16.66%

How automation in molecular diagnostics is redefining laboratory workflows, quality expectations, and strategic priorities across clinical and research environments

Automation is no longer an incremental improvement for molecular diagnostics laboratories; it has become a strategic imperative that affects clinical throughput, data integrity, and operational resilience. Advances in robotics, integrated sample processing, and cloud-enabled data analysis are converging with evolving clinical needs to create a landscape where laboratories can reduce hands-on time, standardize protocols, and deliver faster, more reproducible results. As a result, automation influences not only day-to-day operations but also capital planning, workforce development, and vendor selection.

Moreover, the drivers of automation extend beyond simple efficiency gains. Regulatory expectations for traceability and quality, the need to scale testing during infectious disease surges, and the demand for complex genomic assays in oncology and hereditary disease testing all push laboratories toward higher degrees of automation. In turn, suppliers respond with modular architectures, scalable software platforms, and expanded service models. Consequently, stakeholders must view automation as a systems-level change that intersects with clinical strategy, IT infrastructure, and supply chain management.

Key transformative shifts in the molecular diagnostics landscape driven by integrated automation, interoperable software, and evolving clinical and operational demands

The molecular diagnostics landscape is experiencing transformative shifts driven by technology maturation, workflow integration, and changing clinical demand. Sequencing platforms and high-throughput PCR systems now coexist with sample-to-answer microarray solutions and sophisticated data analysis tools, enabling laboratories to broaden their test menus and reduce turnaround times. At the same time, software-enabled orchestration and cloud-based analytics are making it feasible to manage complex multi-instrument workflows with greater transparency and auditability.

Transitioning from fragmented instrument fleets to integrated automation ecosystems also alters procurement approaches and vendor relationships. Suppliers that deliver interoperability, validated workflows, and long-term service agreements gain strategic advantage. Meanwhile, laboratories prioritize solutions that reduce manual interventions, limit contamination risk, and enable remote monitoring. Taken together, these shifts are driving consolidation of point technologies into end-to-end solutions, aligning technical innovation with clinical and operational imperatives.

Assessing how evolving United States tariff policies influence procurement, supply chain resilience, and strategic sourcing decisions across diagnostics manufacturers and laboratories

Recent tariff developments and trade policy changes in the United States have influenced the procurement and supply dynamics for molecular diagnostics equipment, consumables, and software. Laboratories and diagnostic suppliers face an evolving cost structure that affects sourcing choices, inventory strategies, and contractual negotiations. As tariffs alter the relative economics of imported components and finished products, organizations reassess supplier footprints and consider alternative manufacturing locations or local stocking strategies to mitigate exposure and preserve continuity of care.

In response to these trade-induced pressures, industry participants increasingly emphasize supplier diversification and nearshoring. Procurement teams work to redesign contracts with clearer clauses for tariffs, duties, and lead-time variability while supply chain teams collaborate with logistics partners to maintain buffer inventories without sacrificing cold-chain integrity. Concurrently, manufacturers respond by optimizing bill-of-materials, qualifying alternate suppliers, and in some cases accelerating regional manufacturing investments. The cumulative effect reshapes commercial conversations around pricing transparency, service commitments, and risk-sharing arrangements, prompting both buyers and sellers to adopt more resilient, collaborative procurement models.

Comprehensive segmentation insights highlighting how product categories, end users, technologies, automation levels, and applications determine adoption, value, and vendor strategies

Segmentation analysis reveals how product type, end user, technology, automation level, and application areas shape adoption patterns and value realization across the diagnostics ecosystem. Based on product type, offerings range from consumables and reagents-encompassing microarray chips, next-generation sequencing library preparation kits, and PCR kits-to instruments such as microarray systems, NGS instruments, and PCR instruments, as well as software and services that include data analysis platforms, integration services, and managed services. These categories interact: instrument adoption often drives recurring consumable demand while software and services facilitate higher-value use cases and operational scalability.

Based on end user, adoption trajectories diverge among clinical laboratories, hospital laboratories, pharmaceutical and biotechnology companies, reference laboratories, and research laboratories. Each segment prioritizes different performance attributes: clinical laboratories emphasize throughput and regulatory compliance, hospital labs focus on rapid turnaround for patient care, pharmaceutical and biotech customers seek scalability for drug development workflows, reference laboratories value consolidation and automation economies, and research labs often prioritize flexibility and cutting-edge capabilities. Based on technology, choices center on microarrays, NGS, and PCR, with each modality offering distinct trade-offs in sensitivity, resolution, and workflow complexity. Automation level further stratifies the landscape into fully automated systems, semi-automated systems, and walkaway automation, each balancing capital intensity against labor savings. Finally, application areas such as cardiovascular disease screening, genetic testing, infectious disease diagnostics, oncology, and women's health create specialized requirements for sample throughput, assay validation, and data interpretation. By synthesizing these segmentation axes, stakeholders can align product roadmaps, service offerings, and commercialization strategies with the differentiated needs of laboratory segments and clinical applications.

Regional insights illustrating how distinct clinical infrastructure, procurement practices, and regulatory environments in the Americas, EMEA, and Asia-Pacific shape automation adoption and commercialization

Regional dynamics shape technology adoption, reimbursement pathways, and supply chain priorities across the molecular diagnostics landscape. In the Americas, advanced laboratory networks and consolidated reference labs drive demand for high-throughput automation and integrated data platforms, while investments in infrastructure and a focus on scale encourage vendor partnerships that emphasize service and local support. In contrast, the Europe, Middle East & Africa region presents a heterogeneous picture: many markets pursue harmonized regulatory frameworks and centralized genomic initiatives, yet infrastructure variability and fragmented procurement practices require flexible, modular solutions that can operate across diverse clinical contexts.

Meanwhile, Asia-Pacific demonstrates rapid adoption of automation in both centralized and decentralized testing environments, supported by strong domestic manufacturing capabilities in several markets and a growing emphasis on genomic medicine. These regional differences affect vendor go-to-market strategies, with successful suppliers tailoring distribution models, validation packages, and training services to local regulatory regimes and laboratory maturity levels. Consequently, regional insight must inform any commercialization plan, supply chain design, and customer engagement approach to ensure compatibility with local clinical workflows and procurement expectations.

Key company strategies reveal how platform integration, modular architectures, service excellence, and regulatory expertise differentiate competitive positioning and vendor selection

Leading companies in the molecular diagnostics automation space follow differentiated strategies that reflect technological strengths, service models, and route-to-market choices. Some vendors prioritize platform-based approaches that integrate instruments, consumables, and software to lock in long-term recurring revenue and ensure validated end-to-end workflows. Others compete on modularity and open-architecture systems that appeal to customers seeking flexibility and the ability to mix and match instruments from multiple suppliers. Across both approaches, investments in connectivity, remote monitoring, and lifecycle services increasingly determine competitive positioning.

Moreover, successful organizations emphasize regulatory expertise and global service footprints to reduce adoption friction for customers operating across jurisdictions. Partnerships with laboratory networks and strategic alliances with software providers accelerate time-to-implementation and broaden addressable use cases. Additionally, several companies leverage scale in manufacturing and distribution to improve supply reliability and absorb logistical challenges. For buyers, this translates into evaluating suppliers not only on instrument performance but also on their ability to deliver validated workflows, dependable service, and long-term roadmap alignment that supports evolving clinical needs.

Actionable recommendations for laboratory executives and vendors to align automation investments with clinical priorities, supply chain resilience, workforce transformation, and interoperability goals

Industry leaders should adopt a proactive posture to capture the benefits of automation while managing risk across clinical, operational, and commercial domains. First, align automation investments with clinical priorities by piloting solutions that address high-volume, high-impact assays and that demonstrate reproducible gains in turnaround time and error reduction. Simultaneously, develop workforce transition plans that reskill laboratory staff for automation oversight, data interpretation, and instrument maintenance to maximize return on technology investments.

Second, strengthen supply chain resilience through multi-source sourcing strategies, regionally diversified inventory, and contractual terms that account for tariff and logistics variability. Third, prioritize interoperability and data standards when procuring instruments and software to facilitate integration with laboratory information systems and to enable scalable analytics. Fourth, negotiate service-level agreements that include remote diagnostics, preventative maintenance, and clear escalation pathways to minimize downtime. Finally, pursue strategic partnerships with vendors that offer validated workflows and training programs, thereby reducing deployment risk and accelerating clinical adoption. By combining these tactical moves into a cohesive automation roadmap, organizations can sustain operational continuity while unlocking higher-value molecular diagnostics capabilities.

A rigorous mixed-methods research approach combining stakeholder interviews, technical validation, secondary literature, and scenario analysis to produce reliable, application-oriented insights

The research methodology synthesizes primary and secondary evidence, qualitative interviews, and technical validation to ensure robust, actionable insights. Primary research included structured interviews with laboratory directors, procurement leaders, and senior technical staff across clinical, hospital, reference, pharmaceutical, and research laboratory settings to capture firsthand perspectives on automation drivers, barriers, and implementation outcomes. These interviews informed deeper analysis of workflow requirements, staffing implications, and technology selection criteria.

Secondary research drew on peer-reviewed literature, regulatory guidance, company technical documentation, and supply chain data to validate product capabilities, integration standards, and service models. Integrative analysis used cross-validation techniques to reconcile stakeholder testimony with documented performance characteristics and published case studies. In addition, scenario analysis examined procurement and tariff sensitivities, while technology maturity assessments evaluated readiness levels for different automation modalities. Throughout, quality control processes ensured transparency in data sources and reproducibility of conclusions, enabling decision-makers to apply findings with confidence in operational planning and vendor selection.

Concluding synthesis emphasizing how strategic automation adoption transforms diagnostic capability, operational resilience, and clinical value delivery across laboratory environments

Automation in molecular diagnostics has moved from a niche efficiency play to a central element of laboratory strategy, affecting how organizations deliver diagnostics, manage risk, and compete in value-based healthcare settings. Integrated automation reduces manual variability, improves throughput, and enables complex genomic workflows that were previously constrained by labor and instrumentation fragmentation. As a result, laboratories that adopt automation strategically gain advantages in turnaround time, reproducibility, and the ability to scale novel assays into routine practice.

Looking ahead, the interplay between technology providers, laboratories, and regulatory frameworks will determine the pace and pattern of adoption. Organizations that prioritize interoperability, supply chain resilience, and workforce readiness will navigate disruptions more effectively and capitalize on opportunities to extend services and enter new clinical domains. In sum, automation represents both a technological enabler and a business lever; when applied thoughtfully, it transforms laboratory capability and supports higher-quality patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automation in the Molecular Diagnostics Market, by Product Type

  • 8.1. Consumables & Reagents
    • 8.1.1. Microarray Chips
    • 8.1.2. Ngs Library Prep Kits
    • 8.1.3. Pcr Kits
  • 8.2. Instruments
    • 8.2.1. Microarray Systems
    • 8.2.2. Ngs Instruments
    • 8.2.3. Pcr Instruments
  • 8.3. Software & Services
    • 8.3.1. Data Analysis Software
    • 8.3.2. Integration Services
    • 8.3.3. Managed Services

9. Automation in the Molecular Diagnostics Market, by Technology

  • 9.1. Microarrays
  • 9.2. Ngs
  • 9.3. Pcr

10. Automation in the Molecular Diagnostics Market, by Automation Level

  • 10.1. Fully Automated Systems
  • 10.2. Semi-Automated Systems
  • 10.3. Walkaway Automation

11. Automation in the Molecular Diagnostics Market, by Application

  • 11.1. Cardiovascular Diseases
  • 11.2. Genetic Testing
  • 11.3. Infectious Disease
  • 11.4. Oncology
  • 11.5. Women's Health

12. Automation in the Molecular Diagnostics Market, by End User

  • 12.1. Clinical Laboratories
  • 12.2. Hospital Laboratories
  • 12.3. Pharmaceutical & Biotechnology Companies
  • 12.4. Reference Laboratories
  • 12.5. Research Laboratories

13. Automation in the Molecular Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automation in the Molecular Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automation in the Molecular Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Automation in the Molecular Diagnostics Market

17. China Automation in the Molecular Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Adaltis S.r.l.
  • 18.7. altona Diagnostics GmbH
  • 18.8. AstraGene LLC
  • 18.9. Becton, Dickinson and Company
  • 18.10. Biocartis NV
  • 18.11. bioMerieux S.A.
  • 18.12. Bruker Corporation
  • 18.13. Danaher Corporation
  • 18.14. DiaSorin S.p.A.
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. Hologic, Inc.
  • 18.17. Hudson Robotics, Inc.
  • 18.18. Laboratory Corporation of America Holdings
  • 18.19. MEGAROBO technologies Co., Ltd.
  • 18.20. Olympus Corporation
  • 18.21. Synchron Lab Automation
  • 18.22. Sysmex Corporation
  • 18.23. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY CHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS LIBRARY PREP KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INTEGRATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEMI-AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WALKAWAY AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WOMEN'S HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 220. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. NATO AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA AUTOMATION IN THE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)